GemVax Signs CRO Contract for 'GV1001' Phase 2 Trial in the US
[Asia Economy Reporter Chunhee Lee] GemVax recently announced on the 18th that it has signed a contract with ICON, a global Contract Research Organization (CRO), for a Phase 2 clinical trial of Alzheimer's disease in the United States.
ICON is a global CRO based in Ireland that rapidly rose to become the third-largest CRO worldwide in revenue last year after acquiring PRA Health Sciences in the U.S. for approximately $12 billion (about 16 trillion KRW) through a merger and acquisition (M&A).
For the U.S. Phase 2 trial, GemVax is currently selecting institutions and undergoing Institutional Review Board (IRB) reviews at each site. Through this contract, they plan to proceed with rapid patient recruitment.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
A GemVax representative stated, "It is true that the clinical trial progress has been delayed for various reasons," adding, "We plan to conduct the trial as quickly as possible through collaboration with ICON, which has become one of the global top 3 CROs through recent M&A."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
